Please login to the form below

Not currently logged in
Email:
Password:

Novo's world-leading insulin plant to get even bigger

Danish firm invests €54m in Kalundborg expansion
Novo Nordisk Kalundborg

Novo Nordisk's product plant in Kalundborg, Denmark - already the largest insulin manufacturing site in the world - is set for further expansion.

The Danish diabetes specialist is investing DKK 400m (around €54m) to enlarge the site on the northwestern coast of Zealand by 500m2.

Michael Hallgren, senior vice president and head of production in Kalundborg, said: "The expansion of our production plant highlights our ambition to continue strengthening our presence in Kalundborg.

“The new facilities will give us greater flexibility and enable the installation of equipment that will enhance efficiency and increase the long-term production capacity of the plant.”

The site, which employs some 3,400 people, is a cornerstone of Novo's global production and produces 50% of the world's insulin as well as a range of biopharmaceutical products.

The investment in the plant comes just over a month after Novo won unanimous backing from FDA advisors for the approval of IDeglira, its once-daily, fixed-dose combination Tresiba (insulin degludec) and Victoza (liraglutide).

A groundbreaking for the Kalundborg plant's extension will take place today and work is expected to be completed by the end of 2018.

Article by
Dominic Tyer

4th July 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics